FrancophonIA/ELRC3.0 huggingface dataset:
English: Treatment with lesinurad 200 mg in combination with a xanthine oxidase inhibitor was associated with an increased incidence of serum creatinine elevations, which are related to increased renal uric acid excretion.
Slovenian: Zdravljenje z lesinuradom 200 mg v kombinaciji z zaviralcem ksantin-oksidaze je spremljala večja incidenca zvišanj kreatinina v serumu; ta so povezana z večjim izločanjem sečne kisline v ledvicah.
English: Zurampic slightly decreased exposure of oxypurinol (a URAT1 substrate), the major metabolite of allopurinol; however, the uric acid-lowering effect of the combination with allopurinol was significantly greater than for either substance alone.
Slovenian: Zdravilo Zurampic je rahlo zmanjšalo izpostavljenost glavnemu presnovku alopurinola oksipurinolu (substrat URAT1), toda učinek na znižanje sečne kisline je bil v kombinaciji z alopurinolom bistveno večji kot z vsako posamezno zdravilno učinkovino.
English: In clinical trials, Zurampic was administered with food, because the serum uric acid lowering was improved under fed conditions.
Slovenian: V kliničnih preskušanjih so zdravilo Zurampic uporabljali s hrano, ker je bilo znižanje sečne kisline v serumu ob uporabi zdravila na poln želodec boljše.
English: Zurampic 200 mg + allopurinol N=405
Slovenian: 200 mg zdravila Zurampic + alopurinol N = 405
English: Female patients of childbearing potential should not rely on hormonal contraception alone when taking Zurampic (see sections 4.4 and 4.5).
Slovenian: Ženske v rodni dobi se med jemanjem zdravila Zurampic ne smejo zanašati le na hormonsko kontracepcijo (glejte poglavji 4.4 in 4.5).
English: What Zurampic looks like and contents of the pack Zurampic 200 mg: a blue, oval, dimensions 5.7 x 12.9 mm, film-coated tablet, engraved with “LES200” on one side.
Slovenian: Zurampic 200 mg: modre filmsko obložene tablete ovalne oblike, velikosti 5,7 x 12,9 mm z vtisnjeno oznako “LES200” na eni strani.
English: Zurampic tablets must be co-administered at the same time as the morning dose of a xanthine oxidase inhibitor, i.e. allopurinol or febuxostat.
Slovenian: Tablete zdravila Zurampic je treba vzeti hkrati z jutranjim odmerkom zaviralca ksantin-oksidaze, tj. alopurinola ali febuksostata.
English: Warnings and precautions Talk to your doctor or pharmacist before taking Zurampic.
Slovenian: Opozorila in previdnostni ukrepi Pred začetkom jemanja zdravila Zurampic se posvetujte z zdravnikom ali farmacevtom.
English: Serious renal-related adverse reactions, e.g. acute renal failure and renal impairment, were reported in patients treated with lesinurad 400 mg (1%) and placebo (0.4%) and in no patients on lesinurad 200 mg.
Slovenian: Resne neželene učinke na ledvicah, npr. akutno ledvično odpoved in okvaro ledvic so zabeležili pri bolnikih, ki so prejemali 400 mg lesinurada (1 %) in placebo (0,4 %), ne pa pri bolnikih, ki so prejemali 200 mg lesinurada.
English: No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh classes A and B) (see section 5.2).
Slovenian: Bolnikom z blago ali zmerno okvaro jeter (Child-Pugh razred A in B) odmerka ni treba prilagoditi (glejte poglavje 5.2).
English: Severe renal impairment (CrCL less than 30 mL/min), end-stage renal disease, kidney transplant recipients or patients on dialysis (see section 4.2).
Slovenian: Huda okvara ledvic (očistek kreatinina manj kot 30 ml/min), končna odpoved ledvic, prejemniki presajene ledvice in bolniki na dializi (glejte poglavje 4.2).
English: Zurampic 200 mg + febuxostat 80 mg N=59
Slovenian: 200 mg zdravila Zurampic + 80 mg febuksostata N = 59
English: Lesinurad is a substrate of OATP1B1, OAT1, OAT3 and OCT1.
Slovenian: Lesinurad je substrat OATP1B1, OAT1, OAT3 in OCT1.
English: Including the combination long-term extension studies, the incidences of serious renal-related adverse reactions (including acute renal failure) per 100 patientyears of exposure were 0.4 and 1.4 for Zurampic 200 mg and Zurampic 400 mg in combination with a xanthine oxidase inhibitor, respectively (see sections 4.2 and 4.4).
Slovenian: Upoštevaje dolgoročna podaljšanja študij kombiniranega zdravljenja je bila incidenca resnih neželenih učinkov na ledvicah (vključno z akutno odpovedjo ledvic) na 100 bolnik-let izpostavljenosti v kombinaciji z zaviralcem ksantin-oksidaze z 200 mg zdravila Zurampic 0,4 in s 400 mg zdravila Zurampic 1,4 (glejte poglavji 4.2 in 4.4).
English: In a 6-month double-blind, placebo-controlled monotherapy study of Zurampic, renal-related adverse reactions and serious renal-related adverse reactions (including acute renal failure) were reported in 17.8% and 4.7% of patients respectively, receiving Zurampic 400 mg alone and in no patients receiving placebo (see sections 4.2 and 4.4).
Slovenian: V 6-mesečni dvojno slepi, s placebom kontrolirani študiji monoterapije z zdravilom Zurampic so se neželeni učinki na ledvicah pojavili pri 17,8 % in resni neželeni učinki (vključno z akutno ledvično odpovedjo) pri 4,7 % bolnikov, ki so prejemali le 400 mg zdravila Zurampic, in pri nobenem od bolnikov, ki so prejemali placebo (glejte poglavji 4.2 in 4.4).
English: Fifty percent of patients had a baseline sUA ≥5.0 mg/dL, which was after 3 weeks of treatment with febuxostat alone.
Slovenian: Petdeset odstotkov bolnikov je imelo izhodiščno (tj. po 3 tednih zdravljenja s samim febuksostatom) SKs ≥ 5,0 mg/dl.
English: Since the incidence of severe renal-related adverse events was increased with the monotherapy as compared to the combination therapy with a xanthine oxidase inhibitor, Zurampic should not be used as monotherapy (see sections 4.2 and 5.1).
Slovenian: Incidenca hudih neželenih učinkov na ledvicah je bila med monoterapijo večja kot med kombiniranim zdravljenjem z zaviralcem ksantin-oksidaze, zato se zdravila Zurampic ne sme uporabljati v monoterapiji (glejte poglavji 4.2 in 5.1).
English: Effect of lesinurad on other medicinal products
Slovenian: Vpliv lesinurada na druga zdravila:
English: Name and address of the manufacturer responsible for batch release
Slovenian: Ime in naslov izdelovalca, odgovornega za sproščanje serij Grünenthal GmbH
English: The stability of the sustained response was demonstrated with a greater proportion of patients treated with Zurampic 200 mg in combination with allopurinol achieving the target serum uric acid level at each visit for 3 consecutive months (Months 4, 5 and 6) compared to patients treated with placebo in combination with allopurinol (see Table 2).
Slovenian: Stabilen trajen odziv so dokazali z večjim deležem bolnikov, zdravljenih s kombinacijo 200 mg zdravila Zurampic in alopurinola, ki so dosegli ciljno koncentracijo sečne kisline na vsakem od obiskov 3 mesece zapored (4., 5. in 6. mesec), v primerjavi z bolniki, ki so jemali placebo v kombinaciji z alopurinolom (glejte preglednico 2) .
English: Salicylates at doses higher than 325 mg per day may decrease the serum uric acid lowering activity of lesinurad and should not be co-administered with Zurampic.
Slovenian: Salicilati lahko v odmerkih nad 325 mg oslabijo vpliv lesinurada na znižanje sečne kisline v serumu in se jih ne sme uporabljati skupaj z zdravilom Zurampic.
English: In the randomised, double-blind, placebo-controlled combination therapy clinical studies, the incidences of patients with adjudicated Major Adverse Cardiovascular Events (CV death, non-fatal myocardial infarction or non-fatal stroke) per 100 patient-years of exposure were: 0.71 (95% CI 0.23, 2.21) for placebo, 0.96 (95% CI 0.36, 2.57) for Zurampic 200 mg, and 1.94 (95% CI 0.97, 3.87) for Zurampic 400 mg, when used in combination with a xanthine oxidase inhibitor.
Slovenian: V randomiziranih, dvojno slepih, s placebom kontroliranih kliničnih študijah kombiniranega zdravljenja je bila pojavnost bolnikov s presojenimi večjimi srčno-žilnimi neželenimi učinki (Major Adverse Cardiovascular Events - MACE: srčno-žilna smrt, miokardni infarkt brez smrtnega izida ali možganska kap brez smrtnega izida) med uporabo v kombinaciji z zaviralcem ksantin-oksidaze na 100 bolnik-let izpostavljenosti: 0,71 (95 % IZ 0,23, 2,21) s placebom, 0,96 (95 % IZ 0,36, 2,57) z 200 mg zdravila Zurampic in 1,94 (95 % IZ 0,97, 3,87) s 400 mg zdravila Zurampic.
English: injections, patches and implants - rifampin - to treat tuberculosis - warfarin - to prevent and treat blood clots forming in the legs, lungs, brain and heart.
Slovenian: motenj razpoloženja in preprečevanje migrene - sildenafil - za zdravljenje motnje erekcije - kontracepcijska sredstva - uporabljajo se za preprečevanje nosečnosti in vključujejo peroralne kontraceptive (kontracepcijske tabletke), kontracepcijske injekcije, obliže in vsadke - rifampicin - za zdravljenje tuberkuloze - varfarin - za preprečevanje in zdravljenje krvnih strdkov v nogah, pljučih, možganih in srcu.
English: Two litres is a good amount to drink.
Slovenian: Primerno je, da zaužijete 2 litra tekočine.
English: Among serious renal-related adverse reactions: renal failure, renal failure acute and renal impairment were reported in 1.9%, 1.9% and 0.9% respectively, of patients receiving lesinurad 400 mg monotherapy and in no patients receiving placebo.
Slovenian: Med resnimi neželenimi učinki na ledvicah so odpoved ledvic, akutno odpoved ledvic oziroma okvaro ledvic zabeležili pri 1,9 %, 1,9 % oziroma 0,9 % bolnikov, ki so prejemali monoterapijo z lesinuradom in pri nobenem od bolnikov, ki so prejemali placebo.
English: Zurampic as add-on to allopurinol in inadequate responders CLEAR1 and CLEAR2 enrolled patients with gout who were on a stable dose of allopurinol of at least 300 mg (or 200 mg for moderate renal impairment), had serum uric acid levels greater than 6.5 mg/dL and reported at least 2 gout flares in the previous 12 months.
Slovenian: Zdravilo Zurampic kot dodatek alopurinolu pri bolnikih z nezadostnim odzivom Študiji CLEAR1 in CLEAR2 sta zajeli bolnike s protinom, ki so dobivali stabilen odmerek vsaj 300 mg alopurinola (oz. 200 mg v primeru zmerne okvare ledvic), so imeli koncentracijo sečne kisline v serumu več kot 6,5 mg/dl in so imeli v preteklih 12 mesecih vsaj 2 napada protina.
English: Figure 1 Mean serum uric acid levels in pooled clinical studies with Zurampic in combination with allopurinol in patients with inadequate response (sUA ≥6 mg/dL) to allopurinol alone
Slovenian: Slika 1 Povprečna koncentracija sečne kisline v serumu kumulativno v kliničnih študijah s kombinacijo zdravila Zurampic in alopurinola pri bolnikih, ki se niso zadostno odzvali (SKs ≥ 6 mg/dl) na sam alopurinol
English: Renal events
Slovenian: Ledvični dogodki
English: Zurampic is administered as a 50:50 mixture of lesinurad atropisomers.
Slovenian: Zdravilo Zurampic se uporablja kot mešanica atropizomerov lesinurada v razmerju 50:50.
English: You must use Zurampic together with either allopurinol or febuxostat.
Slovenian: Zdravilo Zurampic morate uporabljati skupaj z alopurinolom ali febuksostatom.
English: Additional monitoring of lipids and blood pressure is recommended in patients using sensitive CYP3A substrate lipid lowering medicines (such as lovastatin or simvastatin) or antihypertensive medicines (such as amlodipine, felodipine or nisoldipine), since their efficacy may be reduced (see section 4.5).
Slovenian: Prejemnikom hipolipemikov (npr. lovastatina ali simvastatina) ali antihipertenzivov (npr. amlodipina, felodipina ali nisoldipina), ki so občutljivi substrati CYP3A, je priporočljivo dodatno kontrolirati lipide oz. krvni tlak, ker se njihova učinkovitost lahko zmanjša (glejte poglavje 4.5).
English: Zurampic in combination with febuxostat in tophaceous gout CRYSTAL enrolled gout patients with measurable tophi.
Slovenian: Zdravilo Zurampic v kombinaciji s febuksostatom pri tofoznem protinu Študija CRYSTAL je zajela bolnike s protinom, ki so imeli merljive tofe.
English: Clinical outcomes - tophus resolution and reduction In CRYSTAL, the proportion of subjects who experienced a complete resolution (defined as 100% resolution of at least one target tophus and no single tophus showing progression) of ≥1 target tophus was higher in the group treated with Zurampic 200 mg in combination with febuxostat compared with placebo in combination with febuxostat, although the difference was not statistically different (26% compared with 21%).
Slovenian: V študiji CRYSTAL je bil delež bolnikov s popolnim izginotjem (opredeljenim kot 100 % izginotje vsaj enega ciljnega tofa in brez napredovanja katerega koli tofa) ≥ 1 ciljnega tofa večji s kombinacijo 200 mg zdravila Zurampic in febuksostata kot s kombinacijo placeba in febuksostata, a razlika ni bila statistično značilna (26 % v primerjavi z 21 %).
English: Table 3 Proportion of patients with baseline sUA ≥5.0 mg/dLwho achieve target serum uric acid levels (<5 mg/dL) with Zurampic in combination with febuxostat
Slovenian: Preglednica 3 Delež bolnikov z izhodiščno SKs ≥ 5,0 mg/dl, ki so dosegli ciljno koncentracijo sečne kisline v serumu (< 5 mg/dl) z zdravilom Zurampic v kombinaciji s febuksostatom
English: Zurampic must not be initiated in patients with severe renal impairment (CrCL less than 30 mL/min), with end-stage renal disease or in patients on dialysis (see sections 4.3 and 4.4).
Slovenian: Zdravila Zurampic se ne sme uvesti bolnikom s hudo okvaro ledvic (očistek kreatinina manj kot 30 ml/min), končno odpovedjo ledvic in bolnikom na dializi (glejte poglavji 4.3 in 4.4).
English: Proportion of patients who met serum uric acid target (<6.0 mg/dL) N (%)
Slovenian: Delež bolnikov, ki so dosegli ciljno vrednost sečne kisline v serumu (< 6,0 mg/dl) N (%)
English: Zurampic 200 mg tablets lesinurad
Slovenian: Zurampic 200 mg tablete lesinurad
English: Renal-related adverse reactions were reported in patients treated with Zurampic 200 mg (5.7%) and Zurampic 400 mg (11.8%) compared to placebo (4.5%), resulting in discontinuation of treatment in 1.2%, 3.3% and 1%, respectively (see section 4.4).
Slovenian: O neželenih učinkih na ledvicah so poročali pri 5,7 % bolnikov, ki so prejemali 200 mg zdravila Zurampic in 11,8 % bolnikov, ki so prejemali 400 mg zdravila Zurampic v primerjavi s 4,5 % bolnikov, ki so prejemali placebo; ti učinki so povzročili prenehanje zdravljenja pri 1,2 % prvih, 3,3 % drugih in 1 % tretjih (glejte poglavje 4.4).
English: The efficacy of Zurampic 200 mg and 400 mg once daily was studied in 3 multicentre, randomised, double-blind, placebo-controlled clinical studies in 1,537 adult patients (13% of these patients were elderly, ≥65 years old) with hyperuricaemia and gout in combination with a xanthine oxidase inhibitor, allopurinol (CLEAR1 and CLEAR2) or febuxostat (CRYSTAL).
Slovenian: Učinkovitost 200 mg in 400 mg zdravila Zurampic enkrat na dan so proučili v 3 multicentričnih, randomiziranih, dvojno slepih, s placebom kontroliranih kliničnih študijah pri 1.537 odraslih bolnikih (13 % bolnikov je bilo starih ≥ 65 let) s hiperurikemijo in protinom.
English: Atropisomer 1 is extensively metabolised by CYP2C9 whereas atropisomer 2 is minimally metabolised by both CYP2C9 and CYP3A4.
Slovenian: Atropizomer 1 se izdatno presnavlja s CYP2C9, atropizomer 2 pa se le minimalno presnavlja tako s CYP2C9 kot s CYP3A4.
English: Rare cases of hypersensitivity (photodermatosis, photosensitivity reaction, dermatitis allergic, pruritus and urticaria) have been reported with lesinurad during the clinical programme.
Slovenian: V kliničnem programu so bili med uporabo lesinurada opisani redki primeri preobčutljivosti (fotodermatoza, fotosenzibilnostna reakcija, alergijski dermatitis, srbenje in urtikarija).
English: Proportion of patients who met serum uric acid Target (<5.0 mg/dL) N(%)
Slovenian: Delež bolnikov, ki so dosegli ciljno vrednost sečne kisline v serumu (< 5,0 mg/dl) N (%)
English: Tablet coat hypromellose titanium dioxide triacetin
Slovenian: Obloga tablete hipromeloza titanov dioksid triacetin indigotin briljantno modro FCF
English: Patients who are known or suspected to be CYP2C9 poor metabolisers based on previous history or experience with other CYP2C9 substrates should use Zurampic with caution (see section 4.4).
Slovenian: Zdravilo Zurampic je treba previdno uporabljati pri bolnikih, za katere je na podlagi anamneze ali izkušenj z drugimi substrati CYP2C9 znano ali obstaja sum, da so slabi metabolizatorji s CYP2C9 (glejte poglavje 4.4).
English: Lesinurad, when combined with a xanthine oxidase inhibitor, increases uric acid excretion and decreases uric acid production resulting in greater sUA lowering.
Slovenian: Lesinurad v kombinaciji z zaviralcem ksantin-oksidaze poveča izločanje sečne kisline in zmanjša njeno nastajanje ter tako doseže večje znižanje SKs.
English: Metabolism and nutrition disorders
Slovenian: Presnovne in prehranske motnje dehidracija
English: In each of the studies, a greater proportion of patients treated with Zurampic 200 mg in combination with allopurinol compared with placebo in combination with allopurinol achieved a serum uric acid less than 5 mg/dL by Month 6 (CLEAR1: 29% versus 10%; CLEAR2: 35% versus 5%).
Slovenian: V obeh študijah je koncentracijo sečne kisline v serumu manj kot 5 mg/dl do 6. meseca dosegel večji delež bolnikov, ki so dobivali kombinacijo 200 mg zdravila Zurampic in alopurinola, kot tistih, ki so dobivali kombinacijo placeba in alopurinola (CLEAR1: 29 % v primerjavi z 10 %, CLEAR2: 35 % v primerjavi s 5 %).
English: Zurampic when added to febuxostat caused an immediate reduction of the mean serum uric acid levels, as compared to placebo, which was sustained in the long term in those patients who continued treatment.
Slovenian: Febuksostatu dodano zdravilo Zurampic je v primerjavi s placebom povzročilo takojšnje znižanje povprečne koncentracije sečne kisline; pri bolnikih, ki so nadaljevali zdravljenje, je bilo to znižanje stalno in dolgotrajno.
English: In vitro, lesinurad is an inhibitor of OATP1B1, OAT1, OAT3, OAT4 and OCT1 at clinically relevant plasma concentrations.
Slovenian: In vitro lesinurad zavira OATP1B1, OAT1, OAT3, OAT4 in OCT1 v plazemskih koncentracijah, ki so klinično pomembne.
English: Zurampic when added to allopurinol caused an immediate reduction of the mean serum uric acid levels, as compared to placebo, which was sustained in the long term in those patients who continued treatment (see Figure 1).
Slovenian: Alopurinolu dodano zdravilo Zurampic je v primerjavi s placebom povzročilo takojšnje znižanje povprečne koncentracije sečne kisline; pri bolnikih, ki so nadaljevali zdravljenje, je bilo to znižanje stalno in dolgotrajno (glejte sliko 1).
English: Zurampic should not be administered with inhibitors of mEH.
Slovenian: Zdravila Zurampic se ne sme uporabljati z zaviralci mEH.
English: Metabolites are not known to contribute to the uric acid lowering effects of lesinurad.
Slovenian: Ni znano, da bi presnovki pripomogli k delovanju lesinurada na znižanje sečne kisline.
English: Gout flare prophylaxis with colchicine or a nonsteroidal anti-inflammatory drug (NSAID) is recommended for at least 5 months when starting therapy (see section 4.4).
Slovenian: Na začetku zdravljenja je vsaj 5 mesecev priporočljiva profilaksa napadov protina s kolhicinom ali nesteroidnim protivnetnim zdravilom (NSAID - Non-Steroidal Anti-Inflammatory Drug) (glejte poglavje 4.4).
English: In the subgroup of patients with a baseline sUA ≥5.0 mg/dL, after 3 weeks of febuxostat therapy, a significant difference was achieved at all study visits for Zurampic 200 mg in combination with febuxostat compared with placebo in combination with febuxostat (see Table 3).
Slovenian: V podskupini bolnikov z izhodiščno SKs ≥ 5,0 mg/dl (po 3 tednih zdravljenja s febuksostatom) je kombinacija 200 mg zdravila Zurampic in febuksostata v primerjavi s kombinacijo placeba in febuksostata dosegla značilno razliko na vseh obiskih v študiji (glejte preglednico 3).
English: The most common adverse reaction leading to discontinuation of Zurampic was blood creatinine increased
Slovenian: Najpogostejši neželeni učinek, ki je povzročil prenehanje zdravljenja z zdravilom Zurampic, je bilo zvišanje kreatinina v krvi (0,8 %).
English: Although other doses have been studied, the recommended dose of Zurampic is 200 mg once daily in combination with a xanthine oxidase inhibitor.
Slovenian: Raziskani so bili sicer tudi drugi odmerki zdravila Zurampic, a njegov priporočeni odmerek v kombinaciji z zaviralcem ksantinoksidaze je 200 mg enkrat na dan.
English: Campus 21, Liebermannstraße A01/501 2345 Brunn am Gebirge Tel: +43(0)2236 379 550-0
Slovenian: 2345 Brunn am Gebirge Tel: +43(0)2236 379 550-0
English: Zurampic must always be taken together with your morning dose of either allopurinol or febuxostat.
Slovenian: Zdravilo Zurampic morate vedno jemati skupaj z jutranjim odmerkom alopurinola ali febuksostata.
English: Zurampic should not be initiated in kidney transplant recipients.
Slovenian: Zdravila Zurampic se ne sme uvesti bolnikom s presajeno ledvico.
English: CYP2C9 poor metabolisers
Slovenian: Slabi metabolizatorji s CYP2C9
English: (200 mg) in patients with mild renal impairment (eCrCL 60 to 89 mL/min), 20% and 73% higher (200 mg) and 3% and 50% higher (400 mg) in patients with moderate renal impairment (eCrCL 30 to 59 mL/min), and 13% higher and 113% higher (400 mg) in patients with severe renal impairment (eCrCL <30 mL/min).
Slovenian: Po uporabi enkratnega odmerka lesinurada pri bolnikih z okvaro ledvic sta bili Cmax oz. AUC lesinurada v primerjavi s tistima pri normalnem delovanju ledvic: 36 % oz. 30 % večji (200 mg) pri bolnikih z blago okvaro ledvic (ocenjeni očistek kreatinina od 60 do 89 ml/min), 20 % oz. 73 % večja (200 mg) in 3 % oz. 50 % večja (400 mg) pri bolnikih z zmerno okvaro ledvic (ocenjeni očistek kreatinina od 30 do 59 ml/min) ter 13 % večja in 113 % večja (400 mg) pri bolnikih s hudo okvaro ledvic (ocenjeni očistek kreatinina < 30 ml/min).
English: No overall differences in safety of Zurampic were observed in patients with mild or moderate renal impairment (eCrCL of30-89 mL/min) compared to patients with normal renal function (see sections 4.2 and 5.2).
Slovenian: Pri bolnikih z blago ali zmerno ledvično okvaro (ocenjeni očistek kreatinina od30 do 89 ml/min) na splošno niso ugotovili razlik v varnosti zdravila Zurampic v primerjavi z bolniki z normalnim delovanjem ledvic (glejte poglavji 4.2 in 5.2).
English: Each film-coated tablet contains 200 mg lesinurad
Slovenian: Ena filmsko obložena tableta vsebuje 200 mg lesinurada
English: Gout flare prophylaxis with colchicine or an NSAID is recommended for at least 5 months when starting Zurampic therapy (see section 4.2).
Slovenian: Priporočljivo je, da bolnik vsaj 5 mesecev po uvedbi zdravila Zurampic prejema kolhicin ali NSAID za profilakso napadov protina (glejte poglavje 4.2).
English: Primary end-point in patients with renal impairment Consistent with the overall population, the proportion of patients with mild to moderate renal impairment (eCrCL 30-89 mL/min) who achieved target serum uric acid levels at Month 6 was 56% for Zurampic 200 mg versus 29% for placebo when added to allopurinol, and 40% for Zurampic 200 mg versus 26% for placebo when added to febuxostat in patients with baseline sUA ≥5.0 mg/dL.
Slovenian: Primarni opazovani dogodek pri bolnikih z okvaro ledvic Tako kot v celotni populaciji je bil delež bolnikov z blago do zmerno okvaro ledvic (ocenjeni očistek kreatinina od 30 do 89 ml/min) in izhodiščno koncentracijo SKs ≥ 5,0 mg/dl, ki so 6. mesec dosegli ciljno koncentracijo sečne kisline v serumu, 56 % z 200 mg zdravila Zurampic in 29 % s placebom po dodatku alopurinolu, oziroma 40 % z 200 mg zdravila Zurampic in 26 % s placebom po dodatku febuksostatu.
English: In these studies, kidney stone adverse reactions (nephrolithiasis being the most frequent) were reported in patients treated with Zurampic 200 mg (0.6%), Zurampic 400 mg (2.5%) and placebo (1.7%).
Slovenian: V teh študijah so neželene učinke z ledvičnimi kamni (med njimi je bila najpogostejša nefrolitiaza) zabeležili pri 0,6 % bolnikov, ki so prejemali 200 mg zdravila Zurampic, pri 2,5 % bolnikov, ki so prejemali 400 mg zdravila Zurampic in pri 1,7 % bolnikov, ki so prejemali placebo.
English: Zurampic 200 mg film-coated tablets
Slovenian: Zurampic 200 mg filmsko obložene tablete
English: CYP2C9 inhibitors and inducers
Slovenian: Zaviralci in induktorji CYP2C9